Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
  • C12N9/14—Hydrolases (3)
  • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
  • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
  • C12N9/14—Hydrolases (3)
  • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
  • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
  • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
  • C12N9/54—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
  • A61K8/0208—Tissues; Wipes; Patches
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
  • A61K8/66—Enzymes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
  • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
  • A61K2800/86—Products or compounds obtained by genetic engineering
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
  • A61Q19/10—Washing or bathing preparations
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q5/00—Preparations for care of the hair

Definitions

• the present invention relates to serine protease variants and compositions comprising the variants which have decreased immunogenicity relative to their corresponding wild-type serine proteases.
• Enzymes make up the largest class of naturally occurring proteins.
• One class of enzyme includes proteases which catalyze the hydrolysis of other proteins. This ability to hydrolyze proteins has been exploited by incorporating naturally occurring and protein engineered proteases into cleaning compositions, particularly those relevant to laundry applications.
• proteases In the cleaning arts, the mostly widely utilized of these proteases are the serine proteases. Most of these serine proteases are produced by bacterial organisms while some are produced by other organisms, such as fungi. See Siezen, Roland J. et al., "Homology Modelling and Protein Engineering Strategy of Subtilases, the Family of Subtilisin-Like Serine Proteases", Protein Engineering, Vol. 4, No. 7, pp. 719 - 737 (1991). Unfortunately, the efficacy of the wild-type proteases in their natural environment frequently does not translate into the unnatural cleaning composition environment. Specifically, protease characteristics such as, for example, thermal stability, pH stability, oxidative stability and substrate specificity are not necessarily optimized for utilization outside the natural environment of the enzyme.
• proteases are foreign to mammals, they are potential antigens. As antigens, these proteases cause immunological and allergic responses (herein collectively described as immunological responses) in mammals.
• immunological responses immunological responses
• sensitization to serine proteases has been observed in environments wherein humans are regularly exposed to the proteases. Such environments include manufacturing facilities, where employees are exposed to the proteases through such vehicles as uncontrolled dust or aerosolization. Aerosolization can result by the introduction of the protease into the lung, which is the route of protease exposure which causes the most dangerous response.
• protease can also occur in the marketplace, where consumers' repeated use of products containing proteases may cause an allergic reaction.
• Epitopes are those amino acid regions of an antigen which evoke an immunological response through the binding of antibodies or the presentation of processed antigens to T cells via a major histocompatibility complex protein (MHC). Changes in the epitopes can affect their efficiency as an antigen. See Walsh, B.J. and M.E.H. Howden, "A Method for the Detection of IgE Binding Sequences of Allergens Based on a Modification of Epitope Mapping", Journal of Immunological Methods, Vol. 121, pp. 275 - 280 (1989).
• subtilisins include subtilisin BPN'.
• subtilisin BPN' serine proteases commonly known as subtilisins, including subtilisin BPN'.
• the present inventors have herein genetically redesigned such subtilisins to alleviate the immunogenic properties attributed to this epitope region. In so doing, the present inventors have discovered subtilisins 3
• the present proteases are suitable for use in several types of compositions including, but not limited to, laundry, dish, hard surface, skin care, hair care, beauty care, oral, and contact lens compositions.
• the present invention relates to variants of serine proteases having decreased immunogenicity relative to their corresponding wild-type proteases. More particularly, the present invention relates to variants having a modified amino acid sequence of a wild-type amino acid sequence, wherein the modified amino acid sequence comprises a deletion and, optionally, a substitution of one or more of positions 70 - 84 corresponding to subtilisin BPN'. The invention further relates to mutant genes encoding such variants and cleaning and personal care compositions comprising such variants.
• the present invention can comprise, consist of, or consist essentially of any of the required or optional components and / or limitations described herein.
• All component or composition levels are in reference to the active level of that component or composition, and are exclusive of impurities, for example, residual solvents or by-products, that may be present in commercially available sources.
• mutation refers to alterations in gene sequences and amino acid sequences produced by those gene sequences. Mutations may be deletions, substitutions, or additions of amino acid residues to the wild-type protein sequence.
• wild-type refers to a protein, herein specifically a protease, produced by unmutated organisms.
• subtilisin BPN' As used herein, the term "variant" means a protein, herein specifically a protease, having an amino acid sequence which differs from that of the wild-type protease. As referred to herein, while the variants of the present invention are not limited to those of subtilisin BPN', all amino acid numbering is with reference to the amino acid sequence for subtilisin BPN' which is represented by SEQ ID NO:l . The amino acid sequence for subtilisin BPN' is further described by Wells, J.A., E. Ferrari, D.J. Henner, D.A. Estell, and E.Y. Chen, Nucleic Acids Research. Vol. II, 7911 - 7925 (1983), incorporated herein by reference.
• the present inventors have discovered an epitope region in serine proteases which corresponds to positions 70 - 84 of subtilisin BPN'.
• the present inventors have further discovered that one or more amino acid deletions and / or substitutions in the amino acid sequence of a wild-type serine protease provides variants which evoke a deceased allergenic and / or immune response relative to the corresponding wild-type serine protease.
• a variant may be designated by referring to the deleted amino acid positions which characterize the variant.
• a variant of a serine protease having deletions at positions 70, 75, 76, 77, 78, 79, 80, 81, and 82 may be designated as ⁇ 70, 75 - 82.
• substitutions may be indicated by providing the wild-type amino acid residue, followed by the position number, followed by the substituted amino acid residue to be substituted. Wherein the substituted amino acid residue may be any natural amino acid, the symbol "*" is provided. Multiple substitutions comprising a variant are separated by the symbol "+".
• a substitution of valine for glycine at position 70 is designated either Gly70Val or G70V.
• a variant comprising both deletions and substitutions is designated by combining the aforementioned designations.
• an example of a variant having a substitution at both positions 70 and 72, as well as deletions at positions 75 - 82 is designated as ⁇ 75 - 82, G70V + V72A.
• subtilisin-like serine proteases are variants of serine proteases.
• serine protease means a protease which has at least 50%, and preferably 80%, amino acid sequence identity with the sequences for one or more of a subtilisin-like serine protease.
• a discussion relating to subtilisin-like serine proteases and their homologies may be found in Siezen et al., "Homology Modelling and Protein Engineering Strategy of Subtilases, the Family of Subtilisin-Like Serine Proteases", Protein Engineering, Vol. 4, No. 7, pp. 719 - 737 (1991).
• Preferred serine proteases for mutation include subtilisin BPN', subtilisin Carlsberg, subtilisin DY, subtilisin 309, proteinase K, and thermitase.
• the most preferred serine protease for mutation is subtilisin BPN'.
• the variants of the present invention are variants of serine proteases having a modified amino acid sequence of a wild-type amino acid sequence, wherein the modified amino acid sequence comprises a deletion of one or more of positions 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, and 84 (70 - 84) corresponding to BPN'.
• the variants herein are not ⁇ 75 - 83 or ⁇ 71.
• the variants of the present invention comprise a deletion of one or more of positions 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, and 83 (73 - 83), even more preferably one or more of 75, 76, 77, 78, 79, 80, 81, and 82 (75 - 82).
• Preferred variants of the present invention include ⁇ 70, 75 - 82; ⁇ 75 - 82; ⁇ 70, 78, 79; ⁇ 70; ⁇ 75; ⁇ 76; ⁇ 78; ⁇ 79; ⁇ 81; and ⁇ 82.
• the more preferred variants include ⁇ 70, 75 - 82; ⁇ 75 - 82; ⁇ 70, 78, 79; ⁇ 70; ⁇ 78; and ⁇ 79.
• the variants of the present invention may optionally, in addition to the one or more deletions, further comprise a substitution of one or more of positions 70 - 84 corresponding to subtilisin BPN'.
• a deletion has been made at any given position, a substitution cannot be made at that position.
• Substitutions in the epitope region are made by replacing the wild-type amino acid residue with another natural amino acid residue such as one given in Table I.
• Tables 2 - 10 below exemplify non-limiting variants of the present invention. With respect to these tables, in describing the specific mutations the wild-type amino acid residue is given first and the corresponding position number is given second. Table 2 delineates preferred single deletion variants. Tables 3 - 10 delineate preferred variants having one or more deletions and, optionally, one or more substitutions. To illustrate, the first example of Table 3 reads "LEU 82 GLY 83".
• This example is meant to exemplify three different variants: one having deletions at positions 82 and 83 ( ⁇ 82, 83), one having a deletion at position 82 and a substitution at 83 ( ⁇ 82, G83*), and one having a substitution at position 82 and a deletion at position 83 ( ⁇ 83, L82*).
• Table 2 One having deletions at positions 82 and 83 ( ⁇ 82, 83), one having a deletion at position 82 and a substitution at 83 ( ⁇ 82, G83*), and one having a substitution at position 82 and a deletion at position 83 ( ⁇ 83, L82*).
• ASN 76 ASN 77 ILE 79 GLY 80 LEU 82 GLY 83
• ASN 76 ASN 77 ILE 79 GLY 80 VAL 81 LEU 82
• ASN 76 ASN 77 ILE 79 GLY 80 VAL 81 LEU 82 GLY 83
• Table 11 exemplifies non-limiting preferred double mutation variants having one deletions and one or more substitutions:
• stabilizing substitutions may additionally be made in order to, for example, restabilize the protease upon mutation of the epitope region or to enhance the proteolytic activity of the variant.
• stabilizing mutations are well known in the art. Examples of such stabilizing mutations are disclosed in, for example, WO 95/10591, Baeck et al., published April 20, 1995; U.S. Pat. No. 4.914.031. Zukowski et al.. issued April 3, 1990; U.S. Pat. No. 5,470,733, Bryan et al.. issued November 28, 1995; U.S. Pat. No. 5,567,601, Bryan et al..
• Preferred stabilizing mutations include one or more of: I107V; K213R; Y217L; Y217K; N218S; G169A; M50F; Q19E; P5A; S9A; I31L; E156S; G169A; N212G; S188P; T254A; S3C + Q206C; and Q271E.
• the more preferred stabilizing mutations include one or more of P5A; S9A; OIL; E156S; G169A; N212G; S188P; T254A; S3C + Q206C; Q271E; Y217L; and Y217K.
• the most preferred stabilizing mutations include Y217L and Y217K.
• a preferred variant for use in personal care compositions is ⁇ 75 - 83, Y217L.
• the variants are prepared by mutating the nucleotide sequences that code for a wild-type serine protease, thereby resulting in variants having modified amino acid sequences.
• Such methods are well-known in the art; one such method is set forth below:
• a phagemid (pSS-5) containing the wild-type subtilisin BPN' gene (Mitchison, C. and J.A. Wells, "Protein Engineering of Disulfide Bonds in Subtilisin BPN'", Biochemistry, Vol. 28, pp. 4807 - 4815 (1989) is transformed into Escherichia coli dut- ung- strain CJ236 and a single stranded uracil-containing DNA template is produced using the VCSM13 helper phage (Kunkel et al., "Rapid and Efficient Site-Specific Mutagenesis Without Phenotypic Selection", Methods in Enzymology, Vol 154, pp.
• Oligonucleotides are made using a 380B DNA synthesizer (Applied Biosystems Inc.). Mutagenesis reaction products are transformed into Escherichia coli strain MM294 (American Type Culture Collection E. coli 33625). All mutations are confirmed by DNA sequencing and the isolated DNA is transformed into the Bacillus subtilis expression strain PG632 (Saunders et al., "Optimization of the Signal-Sequence 68
• Fermentation is as follows. Bacillus subtilis cells (PG632) containing the variant of interest are grown to mid-log phase in one liter of LB broth containing 10 g/L glucose, and inoculated into a Biostat C fermentor (Braun Biotech, Inc., Allentown, PA) in a total volume of 9 liters.
• the fermentation medium contains yeast extract, casein hydrosylate, soluble - partially hydrolyzed starch (Maltrin M-250), antifoam, buffers, and trace minerals (see "Biology of Bacilli: Applications to Industry", Doi, R. H. and M. McGloughlin, eds. (1992)).
• the broth is kept at a constant pH of 7.5 during the fermentation run. Kanamycin (50 ⁇ g/mL) is added for antibiotic selection of the mutagenized plasmid.
• the cells are grown for 18 hours at 37 °C to an ⁇ ⁇ Q of about 60 and the product harvested.
• the fermentation broth is taken through the following steps to obtain pure variant.
• the broth is cleared of Bacillus subtilis cells by tangential flow against a 0.16 ⁇ m membrane.
• the cell-free broth is then concentrated by ultrafiltration with a 8000 molecular weight cut-off membrane.
• the pH is adjusted to 5.5 with concentrated MES buffer (2-(N-morpholino)ethanesulfonic acid).
• the variant is further purified by cation exchange chromatography with S-sepharose and elution with NaCI gradients, (see Scopes, R. K., "Protein Purification Principles and Practice", Springer- Verlag, New York (1984).
• a /?NA assay (DelMar et al., Analytical Biochemistry, Vol. 99, pp. 316 - 320 (1979)) is used to determine the active variant concentration for fractions collected during gradient elution. This assay measures the rate at which ?-nitroaniline is released as the variant hydrolyzes the soluble synthetic substrate, succinyl-alanine-alanine- proline-phenylalanine- ?-nitroaniline (sAAPF-pNA). The rate of production of yellow color from the hydrolysis reaction is measured at 410 nm on a spectrophotometer and is 69
• an equal weight of propylene glycol is added to the pooled fractions obtained from the chromatography column.
• SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis
• the absolute enzyme concentration is determined via an active site titration method using trypsin inhibitor type II-T: turkey egg white (Sigma Chemical Company, St. Louis, MO).
• the enzyme stock solution is eluted through a Sephadex- G25 (Pharmacia, Piscataway, New Jersey) size exclusion column to remove the propylene glycol and exchange the buffer.
• the MES buffer in the enzyme stock solution is exchanged for 0.1 M tris buffer (tris(hydroxymethyl-aminomethane) containing 0.01M CaCl 2 and pH adjusted to 8.6 with HCI. All experiments are carried out at pH 8.6 in tris buffer thermostated at 25 °C.
• the present variants may be tested for enzymatic activity and immune and / or allergenic response using the following methods, both of which are known to one skilled in the art. Alternatively, other methods well-known in the art may be used.
• protease activity of a variant of the present invention may be assayed by methods which are well-known in the art. Two such methods are set forth herein below: Skin Flake Activity Method
• the tape square is allowed to air-dry.
• the color intensity between the tape square obtained from the control enzyme and the tape square obtained from the variant is compared visually or by using a chromameter. Relative to the control enzyme tape square, a variant tape square showing less color intensity is indicative of a variant having higher activity. Dyed Collagen Activity Method
• T-Cell Proliferation Assay The immune and / or allergenic potential of the variants of the present invention may be determined using a T-cell proliferation assay such as the assay presented 71
• This assay is a variation of the assay disclosed in Bungy Poor Fard et al.. "T Cell Epitopes of the Major Fraction of Rye Grass Lolium perenne (Lol p I) Defined Using Overlapping Peptides in vitro and in vivo", Clinical Experimental Immunology, Vol. 94, pp. 111 - 116 (1993).
• the blood of subjects allergic to subtilisin BPN' (prick test positive) and control subjects (prick test negative) are used in this assay.
• Blood ( ⁇ 60 mL) from each subject is collected and mononuclear cells are harvested using ficoll-hypaque (which may be obtained from Pharmacia, Piscataway, New Jersey).
• the cells are washed twice in RPMI 1640 (which may be obtained from Gibco, Grand Island, New York) and then resuspended in complete medium RPMI supplemented with 10% human AB-serum, 2 mM L-glutamine, and 25 ⁇ g / mL gentamicin (which may be obtained from Gibco).
• Cells are cultured at a concentration of 2 x 10 5 cells / well in 0.2 mL of complete medium in U-bottomed 96-well microtiter plates.
• the potential antigen to be tested (either inactivated BPN' as positive control or a variant of the present invention) is added at a final concentration up to about 40 ⁇ g / mL.
• Cultures are incubated at 37 °C in 5% CO2. After five days, 1 ⁇ Ci / well of methyPH-thymidine is added and 18 hours later the cells are harvested. 3 H-thymidine incorporation by the cell is assessed as a measure of T-cell proliferation by liquid scintillation counting.
• the variants may be utilized in cleaning compositions including, but not limited to, laundry compositions, hard surface cleansing compositions, light duty cleaning compositions including dish cleansing compositions, and automatic dishwasher detergent compositions.
• the cleaning compositions herein comprise an effective amount of one or more variants of the present invention and a cleaning composition carrier.
• effective amount of variant refers to the quantity of variant necessary to achieve the proteolytic activity necessary in the specific cleaning composition. Such effective amounts are readily ascertained by one of ordinary skill in the art and is based on many factors, such as the particular variant used, the cleaning application, the specific composition of the cleaning composition, and whether a liquid 72
• the cleaning compositions comprise from about 0.0001% to about 10%, more preferably from about 0.001% to about 1%, and most preferably from about 0.01% to about 0.1% of one or more variants of the present invention.
• the cleaning compositions comprise from about 0.0001% to about 10%, more preferably from about 0.001% to about 1%, and most preferably from about 0.01% to about 0.1% of one or more variants of the present invention.
• the present cleaning compositions further comprise a cleaning composition carrier comprising one or more cleaning composition materials compatible with the variant.
• cleaning composition material means any material selected for the particular type of cleaning composition desired and the form of the product (e.g., liquid, granule, bar, spray, stick, paste, gel), which materials are also compatible with the variant used in the composition.
• the specific selection of cleaning composition materials is readily made by considering the material to be cleaned, the desired form of the composition for the cleaning condition during use.
• compatible as used herein, means the cleaning composition materials do not reduce the proteolytic activity of the variant to such an extent that the variant is not effective as desired during normal use situations. Specific cleaning composition materials are exemplified in detail hereinafter.
• the variants of the present invention may be used in a variety of detergent compositions where high sudsing and good cleansing activity is desired.
• the variants can be used with various conventional ingredients to provide fully-formulated hard-surface cleaners, dishwashing compositions, fabric laundering compositions, and the like.
• Such compositions can be in the form of liquids, granules, bars, and the like.
• Such compositions can be formulated as "concentrated" detergents which contain as much as from about 30% to about 60% by weight of surfactants.
• the cleaning compositions herein may optionally, and preferably, contain various surfactants (e.g., anionic, nonionic, or zwitterionic surfactants). Such surfactants are typically present at levels of from about 5% to about 35% of the compositions.
• surfactants e.g., anionic, nonionic, or zwitterionic surfactants.
• Such surfactants are typically present at levels of from about 5% to about 35% of the compositions.
• Nonlimiting examples of surfactants useful herein include the conventional C u - C j g alkyl benzene sulfonates and primary and random alkyl sulfates, the CIQ-CIS 73
• alkyl alkoxy sulfates AES
• alkyl alkoxy carboxylates AEC
• the use of such surfactants in combination with the amine oxide and / or betaine or sultaine surfactants is also preferred, depending on the desires of the formulator.
• Other conventional useful surfactants are listed in standard texts. Particularly useful surfactants include the Ci ⁇ -Cjg N-methyl glucamides disclosed in U.S. Pat. No. 5, 194,639, Connor et al.. issued March 16, 1993.
• compositions herein A wide variety of other ingredients useful in detergent cleaning compositions can be included in the compositions herein including, for example, other active ingredients, carriers, hydrotropes, processing aids, dyes or pigments, and solvents for liquid formulations.
• suds boosters such as the lO' i ⁇ alkolamides can be incorporated into the compositions, typically at about 1% to about 10%) levels.
• the C10-C14 monoethanol and diethanol amides illustrate a typical class of such suds boosters.
• Use of such suds boosters with high sudsing adjunct surfactants such as the amine oxides, betaines and sultaines noted above is also advantageous.
• soluble magnesium salts such as MgCl 2 , MgSO and the like, can be added at levels of, typically, from about 0.1% to about 2%, to provide additional sudsing.
• the liquid detergent compositions herein may contain water and other solvents as carriers.
• Low molecular weight primary or secondary alcohols exemplified by methanol, ethanol, propanol, and /so-propanol are suitable.
• Monohydric alcohols are preferred for solubilizing surfactants, but polyols such as those containing from about 2 to about 6 carbon atoms and from about 2 to about 6 hydroxy groups (e.g., 1,3- 74
• propanediol, ethylene glycol, glycerine, and 1 ,2-propanediol can also be used.
• the compositions may contain from about 5% to about 90%, typically from about 10% to about 50% of such carriers.
• the detergent compositions herein will preferably be formulated such that during use in aqueous cleaning operations, the wash water will have a pH between about 6.8 and about 11. Finished products are typically formulated at this range.
• Techniques for controlling pH at recommended usage levels include the use of, for example, buffers, alkalis, and acids. Such techniques are well known to those skilled in the art.
• the formulator may wish to employ various builders at levels from about 5% to about 50% by weight.
• Typical builders include the 1-10 micron zeolites, polycarboxylates such as citrate and oxydisuccinates, layered silicates, phosphates, and the like.
• Other conventional builders are listed in standard formularies.
• the formulator may wish to employ various additional enzymes, such as cellulases, lipases, amylases and proteases in such compositions, typically at levels of from about 0.001% to about 1% by weight.
• additional enzymes such as cellulases, lipases, amylases and proteases
• Various detersive and fabric care enzymes are well-known in the laundry detergent art.
• bleaching compounds such as the percarbonates, perborates and the like
• percarbonates, perborates and the like can be used in such compositions, typically at levels from about 1% to about 15% by weight.
• such compositions can also contain bleach activators such as tetraacetyl ethylenediamine, nonanoyloxybenzene sulfonate, and the like, which are also known in the art. Usage levels typically range from about 1% to about 10% by weight.
• Soil release agents especially of the anionic oligoester type, chelating agents, especially the aminophosphonates and ethylenediaminedisuccinates, clay soil removal agents, especially ethoxylated tetraethylene pentamine, dispersing agents, especially polyacrylates and polyasparatates, brighteners, especially anionic brighteners, suds suppressors, especially silicones and secondary alcohols, fabric softeners, especially smectite clays, and the like can all be used in such compositions at levels ranging from 75
• Enzyme stabilizers may also be used in the cleaning compositions.
• Such enzyme stabilizers include propylene glycol (preferably from about 1% to about 10%), sodium formate (preferably from about 0.1% to about 1%) and calcium formate (preferably from about 0.1% to about 1%).
• hard surface cleaning compositions refers to liquid and granular detergent compositions for cleaning hard surfaces such as floors, walls, bathroom tile, and the like.
• Hard surface cleaning compositions of the present invention comprise an effective amount of one or more variants of the present invention, preferably from about 0.001% to about 10%, more preferably from about 0.01% to about 5%, more preferably still from about 0.05%) to about 1% by weight of variant of the composition.
• such hard surface cleaning compositions typically comprise a surfactant and a water-soluble sequestering builder. In certain specialized products such as spray window cleaners, however, the surfactants are sometimes not used since they may produce a filmy and / or streaky residue on the glass surface.
• the surfactant component when present, may comprise as little as 0.1% of the compositions herein, but typically the compositions will contain from about 0.25% to about 10%, more preferably from about 1% to about 5% of surfactant.
• compositions will contain from about 0.5% to about 50% of a detergency builder, preferably from about 1% to about 10%.
• the pH should be in the range of from about 7 to about 12.
• Conventional pH adjustment agents such as sodium hydroxide, sodium carbonate or hydrochloric acid can be used if adjustment is necessary.
• Solvents may be included in the compositions.
• Useful solvents include, but are not limited to, glycol ethers such as diethyleneglycol monohexyl ether, diethyleneglycol monobutyl ether, ethyleneglycol monobutyl ether, ethyleneglycol monohexyl ether, propyleneglycol monobutyl ether, dipropyleneglycol monobutyl ether, and diols such as 76
• 2,2,4-trimethyl-l,3-pentanediol and 2-ethyl-l,3-hexanediol When used, such solvents are typically present at levels of from about 0.5% to about 15%, more preferably from about 3% to about 11 ).
• volatile solvents such as /s ⁇ -propanol or ethanol can be used in the present compositions to facilitate faster evaporation of the composition from surfaces when the surface is not rinsed after "full strength" application of the composition to the surface.
• volatile solvents are typically present at levels of from about 2% to about 12% in the compositions.
• Hard surface cleaning compositions of the present invention are illustrated by the following examples.
• dishwashing compositions comprise one or more variants of the present invention.
• “dishwashing composition” refers to all forms of compositions for cleaning dishes including, but not limited to, granular and liquid forms. Dishwashing compositions of the present invention are illustrated by the following examples.
• Liquid fabric cleaning compositions of the present invention are illustrated by the following examples. 78
• the present variants are particularly suited for use in personal care compositions such as, for example, leave-on and rinse-off hair conditioners, shampoos, leave-on and rinse-off acne compositions, facial milks and conditioners, shower gels, soaps, foaming and non-foaming facial cleansers, cosmetics, hand, facial, and body lotions and moisturizers, leave-on facial moisturizers, cosmetic and cleansing wipes, oral care compositions, and contact lens care compositions.
• the present personal care compositions comprise one or more variants of the present invention and a personal care carrier.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Wood Science & Technology (AREA)
• Organic Chemistry (AREA)
• Zoology (AREA)
• Genetics & Genomics (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biomedical Technology (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Molecular Biology (AREA)
• Biotechnology (AREA)
• Epidemiology (AREA)
• Microbiology (AREA)
• Birds (AREA)
• Medicinal Chemistry (AREA)
• Biochemistry (AREA)
• General Engineering & Computer Science (AREA)
• Dermatology (AREA)
• Detergent Compositions (AREA)
• Enzymes And Modification Thereof (AREA)
• Cosmetics (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (7)

Applications Claiming Priority (2)

Publications (1)

Family

ID=22150818

Family Applications (1)

Country Status (9)

Cited By (9)

Families Citing this family (3)

Citations (3)

Family Cites Families (2)

• 1999
  • 1999-03-25 KR KR1020007010692A patent/KR20010052223A/ko not_active Application Discontinuation
  • 1999-03-25 BR BR9909147-0A patent/BR9909147A/pt not_active IP Right Cessation
  • 1999-03-25 WO PCT/IB1999/000520 patent/WO1999049057A1/en not_active Application Discontinuation
  • 1999-03-25 JP JP2000538017A patent/JP2002518993A/ja not_active Withdrawn
  • 1999-03-25 CN CN99806571A patent/CN1303437A/zh active Pending
  • 1999-03-25 CA CA002324422A patent/CA2324422A1/en not_active Abandoned
  • 1999-03-25 EP EP99907806A patent/EP1082443A1/en not_active Withdrawn
  • 1999-03-25 AU AU27426/99A patent/AU750336B2/en not_active Ceased
  • 1999-03-26 AR ARP990101373A patent/AR023021A1/es not_active Application Discontinuation

Patent Citations (3)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events